Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1624 1625 1657
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18554778 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | Non-Final OA | Novartis AG |
| 18492734 | COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS | Non-Final OA | ARIBIO CO., LTD. |
| 18365919 | SARS-COV2 MAIN PROTEASE INHIBITORS | Non-Final OA | Gilead Sciences, Inc. |
| 18462373 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES |
| 18335415 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | Non-Final OA | Intervet Inc. |
| 18572862 | TRK KINASE INHIBITOR COMPOUND AND USE THEREOF | Non-Final OA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | Non-Final OA | Betta Pharmaceuticals Co., Ltd |
| 18284654 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 18535503 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 18557191 | (HETERO)ARYLAMIDE COMPOUND AND PEST CONTROL AGENT | Non-Final OA | Nippon Soda Co., Ltd. |
| 18556775 | PREPARATION METHOD OF L-NICOTINE | Non-Final OA | WUHAN QR PHARMACEUTICALS CO., LTD. |
| 18556846 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Non-Final OA | JUBILANT PRODEL LLC |
| 18466730 | PROCESS FOR THE PREPARATION OF IMIDAZOBENZODIAZEPINES | Non-Final OA | ODH IP Corp. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy